Targeting cancer stem cells improves treatment effectiveness and prevents metastasis
This study shows that for the first time, targeting the proliferating tumor mass and dormant cancer stem cells with combination therapy effectively inhibited tumor growth and prevented metastasis compared to monotherapy in mice,” said Wang, who is a member of the UCLA Jonsson Comprehensive Canc er Center and of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. “Our discovery could be applied to other solid tumors such as breast and colon cancer, which also frequently metastasizes to lymph nodes or distant organs.”“With this new and exciting study, Dr. Wang and his team have provided the building blocks for understanding the cellular and genetic mechanisms behind squamous cell carcinoma,” said Dr. Paul Krebsbach, dean of the UCLA School of Dentistry. “The work has important translational values. Small m olecule inhibitors for cancer stem cells in this study are available or being utilized in clinical trials for other diseases. It will be interesting to conduct a clinical trial to test these inhibitors for head and neck squamous cell carcinoma.”Additional authors of the study include Demeng Cheng, first author and postdoctoral scholar in Wang ’s lab; Mansi Wu, Yang Li, Dr. Insoon Chang, Yuan Quan, Mari Salvo, Peng Deng, Dr. Bo Yu, Yongxin Yu, Jiaqiang Dong, John M. Szymanski, Sivakumar Ramadoss and Jiong Li who are all from the laboratory of molecular signaling in the division of oral biology...
Cancer patients get inundated with advice, how much of it can be trusted?
Tumor-derived exosomes promote tumor self-seeding in hepatocellular carcinoma by transferring miRNA-25-5p to enhance cell motility, Published online: 22 May 2018; doi:10.1038/s41388-018-0309-xTumor-derived exosomes promote tumor self-seeding in hepatocellular carcinoma by transferring miRNA-25-5p to enhance cell motility
Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy, Published online: 22 May 2018; doi:10.1038/s41388-018-0314-0Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy
Date: Monday, 06 04, 2018; Speaker: Taro Yamashita, M.D., PhD, Associate Professor, Kanazawa University Hospital; Building: Building 37; 4041
Date: Thursday, 06 07, 2018; Speaker: Claire Vajdic, Ph.D., Head of the Cancer Epidemiology Research Unit, The University of New South Wales; Webinar
Administering androgen deprivation therapy (ADT) to men with low-risk prostate cancer improves some short-term outcomes. But is it still active surveillance? And do otherwise healthy men need treatment?Medscape Medical News
NHS HEROES AWARDS 2018 aired on ITV tonight, and among those leading the tributes were Prince William and the Duchess of Cornwall. One mum was handed an award for raising millions of pounds to fund cancer research after her son lost his three year fight with the disease. The type of cancer he had was rhabdomyosarcoma - what are its symptoms?
The largest cancer meeting in the world is coming up soon, but early release of abstracts means that data to be presented are already making news.Medscape Medical News
San Antonio is getting more than a world-renowned cancer researcher with the addition of Patrick Sung.
The presence and burden of single nucleotide variants as measured in cell-free DNA may have substantial prognostic utility in patients with melanoma who have metastases.
More News: Biology | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Cervical Cancer | Chemotherapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Dentistry | Genetics | Grants | Head and Neck Cancer | HNSCC | Laboratory Medicine | Molecular Biology | Oral Cancer | Skin | Skin Cancer | Squamous Cell Carcinoma | Stem Cell Therapy | Stem Cells | Study